Table 3:

Sensitivity analysis of cancer risk comparing patients with type 2 diabetes who are metformin users or non-users with those without diabetes, within the DM1 and DM1-free cohorts, requiring a minimum of two metformin prescriptions to be considered a user

Analysis*	DM1 Cohort			DM1-free Cohort
	(n=913)			(n=12,318)
	HR	(95% CI)	p-value	HR	(95% CI)	p-value
No Diabetes	Reference			Reference
T2D (metformin non-users)	3.49	(1.15 to 10.6)	0.03	1.16	(0.74 to 1.81)	0.51
T2D (metformin users)	0.44	(0.06 to 3.40)	0.43	1.26	(0.90 to 1.78)	0.18

^*Adjusted for sex, baseline BMI (continuous), linkage status (time-dependent starting April 1997), and number of healthcare encounters (in CPRD and/or HES prior to outcome/end of follow-up date, with a 1-year time lag)